Alto Neuroscience estimates June 30 cash, equivalents and restricted cash at $244.2 million
ANRO•ALTO-207 development plans
The company signaled a clinical strategy shift with an acceleration and expansion of ALTO-207 development.
Alto Neuroscience said it is planning an additional Phase 3 trial of ALTO-207 monotherapy in treatment-resistant depression.
Preliminary June 30 cash balance
Alto Neuroscience estimated cash, cash equivalents and restricted cash of about $244.2 million as of June 30, 2026.
The figure was preliminary and unaudited; the final quarter-end balance could differ materially.
